CMT Research Foundation
  • What is CMT?
    • Types of CMT
      • What is CMT1?
        • What is CMT1A?
        • What is CMT1B?
        • What is HNPP?
      • What is CMT2?
        • What is CMT2A?
      • What is CMT4?
        • What is SORD?
      • What is CMTX?
        • Understanding CMT1X/CMTX1 and GJB1
    • Videos
      • What is CMT?
      • Everything You Need to Know in Five Minutes
      • Demystifying the Drug Development Process
      • How Patients Can Change the Pace of Drug Development
      • How We Get from Today to FDA-Approved Treatments
      • Conversations with Researchers Working in CMT
  • About Us
    • Founders
    • Board of Directors
      • Taking Stock by Peter deSilva
    • Scientific Advisory Board
    • CMT Research Foundation Staff
    • CMT Research Foundation Advisors
    • Contact Us
    • Financials
  • Research
    • Overview
    • Research Pipeline
    • Research News
    • Research We Fund
    • Clinical Trials
    • CMTRF Research Priorities
    • Apply for CMT Research Foundation Funding
  • News
    • News & Stories
  • Take Action
    • Young Professionals Board
    • CMT Research Foundation Ambassadors
    • CMT Clinical Trial Studies
    • CMT1A Endgame
    • Annual Global CMT Research Convention
    • Donate
  • Global CMT Research Convention
  • Donate
Select Page

Give now to accelerate treatments and cures for all types of CMT.

Donate today!

Thomas F. Sander Joins CMT Research Foundation Board of Directors

Apr 27, 2023 | Press Releases

ATLANTA (April 26, 2023) CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth disease, today announced that rare disease sales specialist, Thomas F. Sander, has joined its Board of Directors....

Edritz Javelosa to Join the CMT Research Foundation as Chief Scientific Officer

Apr 17, 2023 | Press Releases

ATLANTA (April 17, 2023) Edritz Javelosa (Hav-a-low-sa), PhD, who has been at the Muscular Dystrophy Association (MDA) since 2019 and Research Portfolio Director since 2021, has joined the CMT Research Foundation (CMTRF) as Chief Scientific Officer.   Reporting to...

The CMT Research Foundation Appoints Anna Combes Vice President of Philanthropy

Apr 10, 2023 | Press Releases

ATLANTA (April 10, 2023) Anna Combes has joined the CMT Research Foundation in the newly-created position of Vice President of Philanthropy.  Reporting to the Chief Operating Officer, Ms. Combes will be responsible for fundraising and development activities, including...

Peter de Silva, Board Member of the CMT Research Foundation and Former Retail President of TD Ameritrade, Publishes Taking Stock

Mar 23, 2023 | Life with CMT, Press Releases

Taking Stock engagingly toggles back and forth between de Silva’s highly successful business career and his quiet battle with CMT ATLANTA (March 23, 2023) Peter de Silva, a nationally recognized and highly accomplished financial industry executive whose career...

CMT Research Foundation Invests in Vanderbilt University School of Medicine to Advance Research for CMT1A

Mar 13, 2023 | CMTRF Funded Research, Press Releases, Research news

ATLANTA (March 13, 2023) The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease*, has invested in a project at Vanderbilt University School of Medicine Basic Sciences that seeks to treat the problem...

CMT Research Foundation Collaborates with Augustine Therapeutics on New Potential Therapy for Charcot-Marie-Tooth Disease

Mar 2, 2023 | CMTRF Funded Research, News, Press Releases, Research news, Small Molecule Therapies

ATLANTA (March 2, 2023) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, is pleased to announce a collaboration with Augustine Therapeutics, a Belgian pharmaceutical company...
« Older Entries

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Gene Therapy
  • Life with CMT
  • News
  • Press Releases
  • Research news
  • Small Molecule Therapies
  • Stories
  • Therapy Types
  • Uncategorized

RSS Important Research News Announcements

  • Macrophages influence Schwann cell myelin autophagy after nerve injury and in a model of Charcot-Marie-Tooth disease May 20, 2023
  • TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A May 5, 2023
  • DGIST Professor Minseok Kim’s team develops an electronic medicine technology that restores abnormal protein behavior, the cause of Charcot-Marie-Tooth Disease (CMT) March 31, 2023
  • Charcot-Marie-Tooth neuropathies: current gene therapy advances and the route towards translation March 25, 2023
  • MFN2-dependent recruitment of ATAT1 coordinates mitochondria motility with alpha-tubulin acetylation and is disrupted in CMT2A March 17, 2023
  • Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice March 16, 2023
  • Restoring Neurofilaments to Axons in a Mouse Model of CMT2E March 1, 2023
  • Full-length isoform sequencing for resolving the molecular basis of Charcot-Marie-Tooth 2A February 8, 2023
  • Torin1 restores proliferation rate in Charcot-Marie-Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation February 3, 2023
  • Novel Variants in MPV17, PRX, GJB1 , and SACS Cause Charcot-Marie-Tooth and Spastic Ataxia of Charlevoix-Saguenay Type Diseases January 30, 2023

This website uses cookies to improve your experience. Full details can be found here. Cookie settingsACCEPT REJECT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
Thanks for Your Interest in CMT Research Foundation!

Sign-up to say up-to-date on research news, as well as drug development and clinical advances.

Sign-Up Now!